$43.80
0.60% yesterday
NYSE, Oct 14, 10:15 pm CET
ISIN
US1101221083
Symbol
BMY

Bristol-Myers Squibb Stock price

$43.80
-2.55 5.50% 1M
-7.54 14.69% 6M
-12.76 22.56% YTD
-8.87 16.84% 1Y
-26.82 37.98% 3Y
-17.20 28.20% 5Y
-18.28 29.45% 10Y
+21.49 96.32% 20Y
NYSE, Closing price Tue, Oct 14 2025
+0.26 0.60%

Key metrics

Basic
Market capitalization
$89.2b
Enterprise Value
$124.7b
Net debt
$35.6b
Cash
$13.6b
Shares outstanding
2.0b
Valuation (TTM | estimate)
P/E
17.7 | 6.7
P/S
1.9 | 1.9
EV/Sales
2.6 | 2.6
EV/FCF
8.6
P/B
5.1
Dividends
DPS
$2.42
Yield 1Y | 5Y
5.5% | 3.5%
Growth 1Y | 5Y
4.8% | 7.6%
Payout 1Y | 3Y
-54.9% | 288.3%
Increased
18 Years
Financials (TTM | estimate)
Revenue
$47.7b | $47.7b
EBITDA
$20.2b | $17.5b
EBIT
$14.4b | $16.1b
Net Income
$5.0b | $13.4b
Free Cash Flow
$14.6b
Growth (TTM | estimate)
Revenue
2.6% | -1.2%
EBITDA
-0.9% | -14.1%
EBIT
30.4% | 39.4%
Net Income
177.2% | 249.8%
Free Cash Flow
12.6%
Margin (TTM | estimate)
Gross
73.9%
EBITDA
42.4% | 36.8%
EBIT
30.3%
Net
10.6% | 28.1%
Free Cash Flow
30.6%
Financial Health
Equity Ratio
17.6%
Return on Equity
-54.8%
ROCE
21.5%
ROIC
15.6%
Debt/Equity
2.8
More
EPS
$2.5
FCF per Share
$7.2
Short interest
1.3%
Employees
34k
Rev per Employee
$1.4m
Show more

Is Bristol-Myers Squibb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Bristol-Myers Squibb Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Bristol-Myers Squibb forecast:

10x Buy
30%
21x Hold
64%
2x Sell
6%

Analyst Opinions

33 Analysts have issued a Bristol-Myers Squibb forecast:

Buy
30%
Hold
64%
Sell
6%

Financial data from Bristol-Myers Squibb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
47,704 47,704
3% 3%
100%
- Direct Costs 12,442 12,442
12% 12%
26%
35,262 35,262
0% 0%
74%
- Selling and Administrative Expenses 7,355 7,355
7% 7%
15%
- Research and Development Expense 9,639 9,639
4% 4%
20%
20,201 20,201
1% 1%
42%
- Depreciation and Amortization 5,759 5,759
38% 38%
12%
EBIT (Operating Income) EBIT 14,442 14,442
30% 30%
30%
Net Profit 5,049 5,049
177% 177%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Bristol-Myers Squibb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bristol-Myers Squibb Stock News

Positive
Seeking Alpha
2 days ago
Bristol Myers Squibb remains undervalued, ranking 12th on my Magic Formula screen with strong earnings yield and capital returns amongst the S&P 500. Company pivoting from small-molecule drugs to mRNA and gene therapies via BioNTech partnership and Orbital Therapeutics acquisition. Growth portfolio offsetting legacy drug declines, but key patents like Eliquis and Opdivo face expirations by 2028.
Neutral
Business Wire
2 days ago
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types.
Neutral
PRNewsWire
2 days ago
REDMOND, Wash. , Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negative breast cancer ineligible for anti-PD(L)1 drugs.
More Bristol-Myers Squibb News

Company Profile

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Head office United States
CEO Christopher Boerner
Employees 34,100
Founded 1933
Website www.bms.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today